Fresenius Kabi
- Country
- 🇧🇪Belgium
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- -
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients with PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Conditions
- Parenteral Nutrition Associated Liver Disease (PNALD)Essential Fatty Acid DeficiencyMalnutritionPediatric ALL
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 40
- Registration Number
- NCT06274788
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Health Service, Fountain Valley, California, United States
🇺🇸Board of Regents of the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
- Conditions
- Malnutrition, ChildMalnutritionEssential Fatty Acid Deficiency (EFAD)Parenteral Nutrition Associated Cholestasis
- Interventions
- Drug: SMOFlipid® (lipid injectable emulsion)
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 100
- Registration Number
- NCT06049680
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care
- Conditions
- Nutrition TherapyCritical Illness
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 56
- Registration Number
- NCT05257031
- Locations
- 🇷🇺
Municipal Clinical Hospital No. 40 of Moscow Healthcare Department, Moscow, Russian Federation
bIosimilar of aDalimumab, an European evAluation
- Conditions
- Ulcerative ColitisRheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisCrohn Disease
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 1050
- Registration Number
- NCT05190484
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
- Conditions
- Ankylosing SpondylitisUlcerative ColitisPsoriatic ArthritisCrohn DiseaseRheumatoid ArthritisPsoriasis
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 754
- Registration Number
- NCT05051943
- Locations
- 🇫🇷
CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
- Conditions
- Neurocognitive DeficitEssential Fatty Acid DeficiencyParenteral Nutrition Associated Liver DiseaseMalnutritionPediatric ALL
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Fresenius Kabi
- Registration Number
- NCT04807478
Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients
- Conditions
- Critical Illness
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 1208
- Registration Number
- NCT04143503
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇧🇪Universitair Ziekenhuis Brussel, Brussels, Belgium
🇧🇪Clinique Universitaire Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium
Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness
- Conditions
- Critical Illness
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 7
- Registration Number
- NCT03992716
- Locations
- 🇫🇷
Hôpital Saint-Antoine, Département d'Anesthésie-Réanimation, Paris, France
🇩🇪Klinikum rechts der Isar, Klinik für Anaesthesiologie, München, Germany
🇵🇱SP ZOZ Wojewódzki Szpital Zespolony im. J. Śniadeckiego, Białystok, Poland
Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition
- Conditions
- Parenteral NutritionSurgery
- Interventions
- Drug: Hospital compounded "All in one" emulsion
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 273
- Registration Number
- NCT03792100
- Locations
- 🇨🇳
The Second Hospital of Jilin University, Changchun, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Efficacy and Safety of SmofKabiven Peripheral Versus Compounded Emulsion
- Conditions
- Parenteral FeedingSurgery
- Interventions
- Drug: Hospital compounded emulsion
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 272
- Registration Number
- NCT03792087
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
🇨🇳Beijing Friendship Hospital Capital Medical University, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China